DALLAS, June 11, 2010 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces an investment report featuring Novavax Inc. (Nasdaq:NVAX). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
The full report is available at: www.microstockprofit.com/lp/NVAX
Novavax Inc. (NVAX) is a clinical-stage biopharmaceutical company focused on creating vaccines that improve upon preventive options for a range of infectious diseases. These vaccines leverage its virus-like particle (VLP) platform technology coupled with a disposable production technology. The Company's product targets include vaccines against the H5N1 and other subtypes of avian influenza with pandemic potential, human seasonal influenza, Varicella Zoster, which causes shingles, and respiratory syncytial virus (RSV). The Company also has a joint venture with Cadila Pharmaceuticals Ltd. to develop and commercialize seasonal influenza virus-like-particle-based vaccine candidates and therapeutic vaccine candidates against cancer, as well as adjuvants, biogeneric products and other diagnostic products for the territory of India. It also has a strategic collaboration with Xcellerex Inc. for the production of 2009 H1N1 influenza vaccine
Message Board Search for NVAX: http://www.boardcentral.com/boards/NVAX
In the report, the analyst notes:
"NVAX reported a net loss of $11.4 million, or $0.11 per share, for the first quarter of 2010 compared to a net loss of $8.3 million, or $0.12 per share, for the first quarter of 2009. The primary reason for the increased loss for the first quarter of 2010 as compared to the same period in 2009 was due to higher research and development spending to support the Company's clinical trials related to its seasonal and H1N1 influenza vaccine candidates.
"CPL Biologicals, a joint venture of Cadila Pharmaceuticals Ltd. and NVAX, recently announced that it has completed construction of its vaccine facility in Dholka, India, and will commence equipment and installation validation this month so that the facility conforms to global standards for production of vaccines for human use."
To read the entire report visit: www.microstockprofit.com/lp/NVAX
See what investors are saying about NVAX at penny stock forum
MicroStockProfit.com is a small-cap research and investment commentary provider. MicroStockProfit.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on MicroStockProfit please visit: http://www.microstockprofit.com.
MicroStockProfit.com Disclosure
MicroStockProfit.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither MicroStockProfit.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, MicroStockProfit.com, for complete risks and disclosures.